Skip to main content

Advertisement

Table 1 Analysis of NUCKS immunostaining in non malignant, non metastatic breast lesions

From: NUCKS overexpression in breast cancer

  Fibroepithelial
tumours
(n=13)
Benign epithelial proliferations
(n = 31)
Intraductal proliferative lesions
(n = 38)
Overall NUCKS
Immuno-
Reactivity
Fibroadenoma
(n = 13)
RR = ns
Adenosis
(n = 20)
RR = ns
Sclerosing adenosis
(n = 11)
R = ns
Usual ductal hyperplasia, UDH
(n = 16), RR = 1.5
Atypical ductal hyperplasia, ADH,
(n = 6), RR = 4.0–5.0
Ductal carcinomas in situ, DCIS
(n = 16), RR = 8.0–11.0
Negative (0) 13(100%) 3 (15%) 1 (9%) 3 (19%)   1 (6%)
+1   10 (50%) 6(55%) 8 (50%) 1 (17%) 2 (12%)
+2   6 (30%) 4(36%) 4 (25%) 2 (33%) 6 (38%)
+3   1 (5%)   1 (6%) 3 (50%) 7 (44%)
Low expression
(0/+1)
13 (100%) 13 (65%) 7 (64%) 11 (69%) 1 (17%) 3 (18%)
High expression (+2/+3)   7 (35%) 4 (36%) 5 (31%) 5 (83%) 13 (82%)
  1. RR = relative risk for subsequent development of invasive breast cancer; ns = non significant